Industrial Perspective on the Manufacturing of Lipid Nanoparticles for Nucleic Acid Delivery
Pharmaceutics · 16.04.2026 · 18 (4) · 489
DOI: 10.3390/pharmaceutics18040489 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 16.04.2026. Verfasst von Jenny Hong Hoang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Merck Life Science KGaA, 64293 Darmstadt, Germany. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have emerged as a groundbreaking delivery platform, revolutionizing the development of nucleic acid-based medicines for gene delivery and gene therapy. This review provides an insightful industrial perspective on the production process of LNPs, focusing on cutting-edge manufacturing equipment, downstream processing and the crucial transition from laboratory to large scale. While LNP production in the discovery phase relies on a small scale (µL to mL) for screening various LNP formulation candidates, transferring to preclinical (up to hundreds of mL) and clinical/commercial scales (up to liters) requires a robust and reproducible manufacturing process. Thus, mixing technologies throughout these scales must be carefully selected and require precision, scalability and high reproducibility to meet the target quality of the LNP drug product. Key mixing technologies in mRNA-LNP production primarily include microfluidic systems and impinging jet mixers (IJMs). In this review, we discuss key critical process parameters (CPPs) in LNP preparation, including flow rate ratio (FRR) or total flow rate (TFR), in relation to associated critical quality attributes (CQAs) across multiple manufacturing scales. We further assess the impact of downstream processing, specifically tangential flow filtration (TFF), on the formulation’s CQAs. In particular, the review highlights the importance of maintaining CQAs along each step of the process and emphasizes the role of robust analytical methods in ensuring product quality and safety. Additionally, we touch on current challenges associated with these advanced delivery vehicles, such as their long-term stability, and introduce the readership to innovative stabilization strategies aimed to extent LNP shelf-life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Merck Life Science KGaA, 64293 Darmstadt, Germany.
- Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69117 Heidelberg, Germany.
ORCID-Profile: Eleni Samaridou
Zitieren
APA
Hong Hoang, J., Ott, M., Samaridou, E., Beck-Broichsitter, M., & Simon, J. (2026). Industrial Perspective on the Manufacturing of Lipid Nanoparticles for Nucleic Acid Delivery. Pharmaceutics, 18(4), 489. https://doi.org/10.3390/pharmaceutics18040489
Vancouver
Hong Hoang J, Ott M, Samaridou E, Beck-Broichsitter M, Simon J. Industrial Perspective on the Manufacturing of Lipid Nanoparticles for Nucleic Acid Delivery. Pharmaceutics. 2026;18(4):489. doi:10.3390/pharmaceutics18040489
BibTeX
@article{HongHoang2026,
author = {Hong Hoang, Jenny and Ott, Melanie and Samaridou, Eleni and Beck-Broichsitter, Moritz and Simon, Johanna},
title = {Industrial Perspective on the Manufacturing of Lipid Nanoparticles for Nucleic Acid Delivery},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {4},
pages = {489},
doi = {10.3390/pharmaceutics18040489}
}
EUVIMED